Evidence map›Paper›PMID 34589864›Full record

ArticleBrain, behavior, & immunity - health2020

Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies.

Jesper Futtrup, Rebecca Margolinsky, Michael Eriksen Benros, Torben Moos, Lisa Juul Routhe, Jørgen Rungby, Jesper Krogh

Open access · goldAbstract read
In one paragraph

Article in Brain, behavior, & immunity - health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Ang II-mediated effects on BBB integrity in psychiatric and neurological disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Association between oxytocin and S100B in community-dwelling older adults.PCN reports : psychiatry and clinical neurosciences · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. The common misconception of blood-brain barrier terminology in psychiatry and neurology.European archives of psychiatry and clinical neuroscience · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jesper FuttrupFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Rebecca MargolinskyFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Michael Eriksen BenrosMental Health Centre Copenhagen, University Hospital of Copenhagen, Copenhagen, Denmark.
Torben MoosLaboratory of Neurobiology, Department of Health Science and Technology, University of Aalborg, Aalborg, Denmark.
Lisa Juul RoutheLaboratory of Neurobiology, Department of Health Science and Technology, University of Aalborg, Aalborg, Denmark.
Jørgen RungbyCopenhagen Center for Translational Research, University Hospital of Bispebjerg, Copenhagen, Denmark.
Jesper KroghDepartment of Endocrinology, University Hospital of Bispebjerg, Copenhagen, Denmark.
University of Copenhagen · DKAalborg University · DKBispebjerg Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBlood-brain barrier (BBB) pathology may be associated with mental disorders. The aim of this systematic review and meta-analysis is to identify, evaluate and summarize available evidence on whether potential biomarkers of BBB pathology are altered in patients with schizophrenia spectrum disorders, major depression and bipolar disorder compared to healthy controls.

methodsThe primary outcome is blood S100B, while secondary outcomes include biomarkers in blood and/or cerebrospinal fluid, i.e. albumin ratio, fibrinogen, immunoglobulin G, glial fibrillary acidic protein, amyloid beta (Aβ), matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases, endothelial glycocalyx constituents, and cell adhesion molecules (CAMs). A systematic search in PubMed, Embase and PsycINFO resulted in 131 eligible studies, of which 93 were included in the meta-analysis. Meta- and subgroup analyses were undertaken using random-effects modelling. The protocol was a priori registered on PROSPERO (CRD42020152721).

resultsS100B was increased in schizophrenia spectrum disorders (24 studies; 1107 patients; standardized mean difference (SMD) ​= ​0.82; 95% confidence interval (CI) ​= ​0.51 to 1.13; I

conclusionsThe findings implicate occurrence of BBB pathology in patients with schizophrenia spectrum disorders, major depression and bipolar disorder compared to healthy controls. However, definite conclusions cannot be drawn, mainly because the investigated biomarkers are indirect measures of BBB pathology.

Indexed as

Albumin ratioBipolar disorderBlood-brain barrierMajor depressionS100BSchizophrenia

Identifiers

PMID34589864
PMCPMC8474159
OpenAlexW3038814902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.